左西孟旦与多巴酚丁胺治疗急性失代偿性心力衰竭疗效和血液学指标比较

目的比较左西孟旦与多巴酚丁胺治疗急性失代偿性心力衰竭的临床效果及对血液学指标的影响。方法选取2018年1月-2019年6月厦门大学附属福州第二医院收治的急性失代偿性心力衰竭患者60例为研究对象,按照随机数字表法分为观察组和对照组各30例。观察组给予左西孟旦治疗,对照组给予多巴酚丁胺治疗。比较2组患者临床疗效及治疗前后血液学指标。结果观察组患者总有效率为90.0%,高于对照组的66.7%(χ2=4.812,P=0.028)。治疗后,2组患者脑钠肽(BNP)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平均低于治疗前,且观察组优于对照组(P<0.01或P<0.05)。结论左西孟旦治疗急性失代偿性心力衰竭效果好,能显著降低BNP、VEGF、MMP-9水平,且不良反应发生率低,值得临床推广。

Comparison of the efficacy and hematological parameters of levosimendan and dobutamine in the treatment of acute decompensated heart failure

Objective To compare the clinical effects of levosimendan and dobutamine in the treatment of acute decompensated heart failure and their effects on hematological parameters.Methods Sixty patients with acute decompensated heart failure who were admitted to the Fuzhou Second Hospital of Xiamen University from January 2018 to June 2019 were selected,and they were divided into observation group(30 cases)and control group(30 cases),according to different treatment schemes.The observation group was treated with levosimendan,and the control group was treated with dobutamine,the clinical efficacy and hematological parameters of the two groups were compared.Results The total effective rate of patients in the observation group(90.0%)was higher than that in the control group(66.7%)(χ2=4.812,P=0.028).After treatment,the levels of BNP,VEGF,and MMP-9 in the two groups were lower than before treatment,and the observation group was lower than the control group(P<0.01 or P<0.05).Conclusion Levosimendan can improve the treatment effect of acute heart failure,reduce the levels of BNP,VEGF and MMP-9,and the incidence of adverse reactions is low,which is worthy of clinical promotion.